Auxilium Pharmaceuticals AUXL
-
Auxilium ( AUXL ) and [[GSK]] plan to jointly sell Auxilium's testosterone gel, Testim, in the U.S. under a deal that will last till Sept. 2015. Also, Auxilium narrows its FY net loss forecast to ...
Auxilium ( AUXL ) and GSK plan to jointly sell Auxilium's testosterone gel, Testim, in the U.S. under a deal that will last till Sept …
-
UPDATE 1-Auxilium, GSK to co-promote testosterone gel in US
May 21 (Reuters) - Auxilium Pharmaceuticals Inc and the U.S. unit of drugmaker GlaxoSmithKline said they will jointly sell Auxilium's testosterone gel, Testim, in the United States.
-
6 Cash Heavy Small-Cap Healthcare Stocks Rated As Buys
By ZetaKap : Interested in following smaller companies? Interested in healthcare stocks? Do you prefer investing in stocks that analysts have weighed in on? Do you value companies holding large amounts of cash? If so, here are some ideas to start your stock search. The Current ratio is a liquidity
-
Auxilium Pharmaceuticals ( AUXL ): Q1 EPS of -$0.04 beats by $0.07. Revenue of $73.6M (+26% Y/Y) beats by $2.4M. (PR)
Auxilium Pharmaceuticals ( AUXL ): Q1 EPS of -$0.04 beats by $0.07 . Revenue of $73.6M (+26% Y/Y) beats by $2.4M . ( PR ) Post your comment!
-
Transcept: The Intermezzo Launch Is Underway
By Smith On Stocks : Investment Opinion and Overview Now is the moment of truth for Transcept ( TSPT ) as the launch of Intermezzo has begun. I recommended Transcept in a report published on January 24, 2012 and I continue to recommend the stock. I would suggest that investors who need a refresher
-
Back On Track: Repros Therapeutics Products Continues Advancement
By Cockrell Group : Kay Nakae, at Ascendiant Capital Markets initiated coverage of Repros Therapeutics ( RPRX ) with a "STRONG BUY" rating and a price target of $6. Repros Therapeutics is a small-cap biotech company that is developing two key products. The first, Androxal, is a once daily, oral ...
-
Auxilium Pharmaceuticals Has The Approvals; Can It Get The Revenue?
… is only a part of the puzzle. Marketing an approved drug is a battle in its own right, as investors in Auxilium Pharmaceuticals ( AUXL ) know all too well. The company has found it difficult to drive market acceptance of its Testim testosterone …
-
Auxilium Pharmaceuticals ( AUXL ): Q4 EPS of -$0.25 misses by $0.09. Revenue of $73.3M (+18.6% Y/Y) in-line. (PR)
Auxilium Pharmaceuticals ( AUXL ): Q4 EPS of -$0.25 misses by $0.09 . Revenue of $73.3M (+18.6% Y/Y) in-line. ( PR ) Post your comment!
-
Seattle Genetics' Adcetris Launch: Second Survey Reveals Additional Insights
… Spectrum Pharmaceuticals ( SPPI ), Incyte ( INCY )/Novartis ( NVS ), Acorda Therapeutics ( ACOR ), and Auxilium Pharmaceuticals ( AUXL ). Seattle Genetics reported $10MM in Adcetris sales for 3Q11, which represented 6 weeks of sales for …
-
Jakafi Launch: Survey Reveals Upside To Stock
By Andrew McDonald : In November of last year, Incyte Corporation ( INCY ) announced FDA approval for its oral JAK inhibitor, Jakafi (ruxolitinib),the first approved treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and ...